Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	100 mg Lasmiditan	744
Overall Study	STARTED	200 mg Lasmiditan	745
Overall Study	STARTED	Placebo	742
Overall Study	Confirmed Eligibility	100 mg Lasmiditan	710
Overall Study	Confirmed Eligibility	200 mg Lasmiditan	695
Overall Study	Confirmed Eligibility	Placebo	705
Overall Study	1st Dose (by 4 Hours Migraine Onset)	100 mg Lasmiditan	630
Overall Study	1st Dose (by 4 Hours Migraine Onset)	200 mg Lasmiditan	609
Overall Study	1st Dose (by 4 Hours Migraine Onset)	Placebo	617
Overall Study	2nd Dose (After 2 Hour Assessment)	100 mg Lasmiditan	289
Overall Study	2nd Dose (After 2 Hour Assessment)	200 mg Lasmiditan	238
Overall Study	2nd Dose (After 2 Hour Assessment)	Placebo	401
Overall Study	COMPLETED	100 mg Lasmiditan	648
Overall Study	COMPLETED	200 mg Lasmiditan	631
Overall Study	COMPLETED	Placebo	643
Overall Study	NOT COMPLETED	100 mg Lasmiditan	96
Overall Study	NOT COMPLETED	200 mg Lasmiditan	114
Overall Study	NOT COMPLETED	Placebo	99

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02439320/flow